The APTIMA V R HPV Assay (AHPV) allows detection of 14 high-risk human papillomavirus (HPV) RNA types in cervical specimens. Until present, the assay has been compared to HPV DNA tests only in triage settings. Herein, we compare AHPV with a DNA assay (Hybrid Capture V R 2; HC2) and liquid-based cyto
β¦ LIBER β¦
Primary screening for cervical cancer precursors by the combined use of liquid-based cytology, computer-assisted cytology and HPV DNA testing
β Scribed by Vassilakos, P; Petignat, P; Boulvain, M; Campana, A
- Book ID
- 109997126
- Publisher
- Nature Publishing Group
- Year
- 2002
- Tongue
- English
- Weight
- 133 KB
- Volume
- 86
- Category
- Article
- ISSN
- 0007-0920
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Evaluation of oncogenic human papillomav
β
Joseph Monsonego; Michael G. Hudgens; Laurent Zerat; Jean-Claude Zerat; Kari Syr
π
Article
π
2010
π
John Wiley and Sons
π
French
β 335 KB
π 2 views
Randomized controlled trial of human pap
β
Marie-Hélène Mayrand; Eliane Duarte-Franco; François Coutlée; Isabel Rodrigues;
π
Article
π
2006
π
John Wiley and Sons
π
French
β 403 KB
π 1 views
## Abstract Since infection with oncogenic human papillomavirus (HPV) has been considered a necessary cause of cervical cancer, tests for oncogenic HPV types have been proposed as adjuncts or replacements to Pap cytology. We designed the Canadian Cervical Cancer Screening Trial (CCCaST) to compare
The probability for a Pap test to be abn
β
Bigras, G; de Marval, F
π
Article
π
2005
π
Nature Publishing Group
π
English
β 118 KB